Study on visible tumors in neurofibromatosis type 1
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have NF1 and have tumors that you or others can see, or you care for a child with NF1 who has such tumors.
- You are at least 8 years old if you have plexiform tumors, or at least 12 years old if you have cutaneous tumors (or both).
- Caregivers must be 18 or older.
- You have internet access and can join a video call or online discussion.
- You can speak and understand English comfortably.
- You are willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for better ways to measure how much tumor activity people with neurofibromatosis type 1 (NF1) have over time. The goal is to develop “biomarkers,” which are test results that may help doctors track disease more easily.
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
This study uses special MRI scans plus computer (AI) analysis to look for early, possibly cancer-related skin or tissue changes in children with neurofibromatosis type 1 (NF1). If it works, it could help doctors detect concerning changes earlier and plan care sooner.
This study looks at how young children with neurofibromatosis type 1 (NF1)—a genetic condition affecting nerve growth—walk and move. Understanding gait patterns may help doctors better support children's development and physical health.
This study checks whether patient surveys (questionnaires) can reliably measure symptoms and pain in people with NF1 who have plexiform neurofibromas. It helps create better tools for tracking how you feel and how treatments may affect quality of life.
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
Hear when a new Neurofibromatosis Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.